Prevalence of Anxiety among Hungarian Subjects with Parkinson’s Disease
Table 3
Comparison of the clinical profile of the Parkinson’s disease patients () with and without anxiety based on the established Parkinson Anxiety Scale threshold value.
No anxiety ()
Presence of anxiety ()
Statistics
Mean or count
SD or percentage
Mean or count
SD or percentage
Age (years)
65.8
9.7
65.9
9.9
NS
Disease duration (years)
7.2
6.1
7.2
7.1
NS
Sex
Male
248
65.4%
92
43.6%
Female
131
34.6%
119
56.4%
Levodopa dosage (in LED mg)
446.7
517.6
517.3
495.0
NS
Dopamine agonist usage (in LED mg)
175.2
212.6
149.7
229.8
NS
Antiparkinson medication (in LED mg)
659.5
600.4
708.0
601.2
NS
Parkinson Anxiety Scale (total score)
6.1
3.7
20.2
6.6
Parkinson Anxiety Scale (Part A)
4.3
2.8
11.5
3.2
Parkinson Anxiety Scale (Part B)
0.9
1.2
5.0
3.1
Parkinson Anxiety Scale (Part C)
0.8
1.2
3.7
2.7
Hamilton Anxiety Scale
10.6
5.7
17.3
6.2
Beck Depression Inventory
7.7
5.8
18.5
8.8
Montgomery-Asberg Depression Rating Scale
8.9
6.0
16.2
7.2
Nonmotor Symptoms Scale
40.5
30.0
76.5
41.5
Montreal Cognitive Assessment
23.2
4.1
21.8
4.7
Mattis Dementia Rating Scale
135.8
8.0
133.7
10.4
Lille Apathy Rating Scale
−24.1
8.3
−19.8
10.9
Parkinson’s Disease Questionnaire
16.7
12.2
32.6
16.8
MDS-UPDRS nM-EDL
10.4
6.2
17.8
7.2
MDS-UPDRS M-EDL
11.8
8.1
17.5
9.6
MDS-UPDRS ME
33.2
15.4
38.0
16.3
MDS-UPDRS MC
3.8
3.2
5.3
3.4
MDS-UPDRS total score
59.2
26.8
78.4
29.6
Antidepressant usage
72
19.0%
178
84.3%
Anxiolytics usage
87
22.9%
162
76.7%
LED = levodopa equivalent dosage; MDS-UPDRS = Movement Disorders Society-sponsored version of Unified Parkinson’s Disease Rating Scale; MDS-UPDRS M-EDL = motor experiences of daily living (Part II of MDS-UPDRS); MDS-UPDRS nM-EDL = nonmotor experiences of daily living (Part I of MDS-UPDRS); SD = standard deviation.
